Table 1 Baseline characteristics of patients with Acinetobacter baumannii infections, stratified by carbapenem susceptibility status
Characteristics | Overall N = 5523 | Carbapenem resistant N = 2047 | Carbapenem susceptible N = 3476 | P value |
|---|---|---|---|---|
Age, years, median (Q1–Q3) | 61 (50.0–72.0) | 63 (54.0–72.0) | 60 (48.0–71.0) | < 0.01 |
Sex, n (%) | 0.01 | |||
Female | 2149 (38.9) | 841 (41.1) | 1308 (37.6) | |
Male | 3374 (61.1) | 1206 (58.9) | 2168 (62.4) | |
Race, n (%) | < 0.01 | |||
White | 3648 (66.1) | 1358 (66.3) | 2290 (65.9) | |
Black | 1155 (20.9) | 500 (24.4) | 655 (18.8) | |
Other | 641 (11.6) | 151 (7.4) | 490 (14.1) | |
Unable to determine | 79 (1.4) | 38 (1.9) | 41 (1.2) | |
Site of index culture infection, n (%) | < 0.01 | |||
Blood | 756 (13.7) | 176 (8.6) | 580 (16.7) | |
Respiratory | 1770 (32.1) | 833 (40.7) | 937 (27.0) | |
Urine | 681 (12.3) | 233 (11.4) | 448 (12.9) | |
Wounda | 1970 (35.7) | 693 (33.9) | 1277 (36.7) | |
Otherb | 346 (6.3) | 112 (5.5) | 234 (6.7) | |
Admission source, n (%) | < 0.01 | |||
Nonhealthcare facility | 3936 (71.3) | 1230 (60.1) | 2706 (77.9) | |
Transfer from other facility/hospital | 1137 (20.6) | 560 (27.4) | 577 (16.6) | |
Transfer from SNF/ intermediate care facility | 345 (6.3) | 237 (11.6) | 108 (3.1) | |
Other/unavailable | 105 (1.9) | 20 (1.0) | 85 (2.5) | |
Days between admission and index culture, n (%) | < 0.01 | |||
1 Day prior to admission | 217 (3.9) | 57 (2.8) | 160 (4.6) | |
Same day as admission | 2500 (45.3) | 734 (35.9) | 1766 (50.8) | |
Day 2 | 907 (16.4) | 407 (19.9) | 500 (14.4) | |
Day 3 | 352 (6.4) | 165 (8.1) | 187 (5.4) | |
Day 4 | 208 (3.8) | 79 (3.9) | 129 (3.7) | |
Day 5 | 178 (3.2) | 93 (4.5) | 85 (2.5) | |
≥ 6 days | 1161 (21.0) | 512 (25.0) | 649 (18.7) | |
Baseline CCI Score | ||||
Median (Q1–Q3) | 3 (2.0–5.0) | 3 (2.0–5.0) | 3 (1.0–5.0) | < 0.01 |
0, n (%) | 647 (11.7) | 145 (7.1) | 502 (14.4) | < 0.01 |
1, n (%) | 730 (13.2) | 227 (11.1) | 503 (14.5) | |
2, n (%) | 939 (17.0) | 383 (18.7) | 556 (16.0) | |
3–5, n (%) | 2115 (38.3) | 843 (41.2) | 1272 (36.6) | |
5 + , n (%) | 1092 (19.8) | 449 (21.9) | 643 (18.5) | |
Baseline comorbidities, n (%) | ||||
At least 1 comorbidity | 4876 (88.3) | 1902 (92.9) | 2974 (85.6) | < 0.01 |
Myocardial infarction | 681 (12.3) | 266 (13.0) | 415 (11.9) | 0.25 |
Congestive heart failure | 1676 (30.4) | 724 (35.4) | 952 (27.4) | < 0.01 |
Peripheral vascular disease | 856 (15.5) | 332 (16.2) | 524 (15.1) | 0.26 |
Cerebrovascular disease | 584 (10.6) | 262 (12.8) | 322 (9.3) | < 0.01 |
Dementia | 345 (6.3) | 177 (8.7) | 168 (4.8) | < 0.01 |
Chronic pulmonary disease | 1798 (32.6) | 780 (38.1) | 1018 (29.3) | < 0.01 |
Peptic ulcer disease | 102 (1.9) | 43 (2.1) | 59 (1.7) | 0.28 |
Liver disease | 514 (9.3) | 157 (7.7) | 357 (10.3) | < 0.01 |
Diabetes | 2558 (46.3) | 1083 (52.9) | 1475 (42.4) | < 0.01 |
Hemiplegia or paraplegia | 826 (15.0) | 442 (21.6) | 384 (11.1) | < 0.01 |
Renal disease | 1849 (33.5) | 772 (37.7) | 1077 (31.0) | < 0.01 |
Any malignancy | 439 (8.0) | 113 (5.5) | 326 (9.4) | < 0.01 |
Metastatic solid tumor | 178 (3.2) | 41 (2.0) | 137 (3.9) | < 0.01 |
Active drug within 72 h on or after index culture datec | 2445 (44.3) | 312 (15.2) | 2133 (61.4) | < 0.01 |